2 completed, 1 terminated, 1 unknown. 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 2, Terminated 1, Unknown 1 |
Follow crenolanib: new trials by email Literature Review of crenolanib trials Research Report on crenolanib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML Crenolanib, Cytarabine, Mitoxantrone - Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations | Phase 3 | Completed | Arog Pharmaceuticals, Inc. | 106 | 2018-08-16 | 2026-04-09 |
| Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML Crenolanib, Midostaurin, Cytarabine - Newly Diagnosed FLT3 Mutated AML | Phase 3 | Completed | Arog Pharmaceuticals, Inc. | 214 | 2018-08-15 | 2026-04-09 |
| Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 Mutations chemotherapy (Mitoxantrone, Cytarabine), Placebo, Crenolanib - Acute Myeloid Leukemia | Phase 3 | Terminated | University of Ulm | 9 | 2016-11-17 | 2021-10-06 |
| Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST Crenolanib, Placebo - GIST With D842V Mutated PDGFRA Gene | Phase 3 | Unknown | Arog Pharmaceuticals, Inc. | 120 | 2016-08-01 | 2021-01-22 |
Recurrence (2) · Leukemia, Myeloid, Acute (1)
Arog Pharmaceuticals, Inc. (3) · University of Ulm (1)
Germany (3) · United States (3) · France (2) · Italy (2) · Spain (2) · Canada (1) · Norway (1) · Poland (1)
Eunice Wang, MD (1) · Jean-Yves Blay, MD (1) · Margaret von Mehren, MD (1)
2015 (1), 2017 (1)